Hybrid Flagellin as a Novel T Cell Independent Vaccine Scaffold
This hybrid flagellin vaccine scaffold may be used to vaccinate individuals with less robust immune systems, including those in the early perinatal period, in people suffering from various T cell immunodeficiency disorders (HIV-AIDS, DiGeorge syndrome), patients undergoing chemotherapy, as well as elderly patients with sluggish adaptive immunity.
None
20180169205
Other Information Related Publication: Bennett, K. M. et al. Hybrid Flagellin as a T Cell Independent Vaccine Scaffold. BMC Biotechnol. 15, 71 (2015). Images Background Vaccines are biological products that are able to establish resistance to specific antigens (diseases) in our bodies, through stimulating the immune system and creating antibodies. While traditional types of vaccines are based on weak live virus, killed virus or bacteria, newer versions are toxoid-based, or genetically engineered (including engineered microbes, subunit vaccines, conjugate vaccines, DNA vaccines, and vector vaccines). Vaccines have a total market size of around $32 billion (2016). This market is estimated to reach the level of nearly $48 billion by 2021, resulting in a compound annual growth rate (CAGR) of 8.3%. Tech ID/UC Case 24323/2014-912-0 Related Cases 2014-912-0
美國
